Eli Lilly and Company announced positive topline results from the TRANSCEND-T2D-1 Phase 3 trial. The investigational drug retatrutide met all primary and secondary endpoints for treating type 2 diabetes. Retatrutide functions as a first-in-class triple hormone receptor agonist targeting GIP, GLP-1, and glucagon.
Patients achieved A1C blood sugar reductions of up to 2.0% over the 40-week study. Participants lost an average of up to 36.6 pounds during the trial. This weight loss represents nearly 17% of total body weight. The weight loss effect continued throughout the entire trial period without plateauing.
The positive data reinforced Lilly's dominant position in the metabolic disease market and generated significant investor interest. The company plans to present detailed results at a medical event in June.